S&P 500   5,044.20 (+0.44%)
DOW   38,010.74 (+0.68%)
QQQ   426.29 (+0.11%)
AAPL   167.99 (+-0.01%)
MSFT   408.28 (-0.86%)
META   508.29 (+2.86%)
GOOGL   155.83 (+0.23%)
AMZN   181.19 (-0.05%)
TSLA   151.23 (-2.71%)
NVDA   848.87 (+1.01%)
AMD   154.98 (+0.62%)
NIO   3.99 (+2.05%)
BABA   69.28 (+0.67%)
T   16.14 (+0.12%)
F   12.11 (+0.58%)
MU   116.53 (+0.17%)
GE   157.67 (+1.28%)
CGC   6.91 (+6.47%)
DIS   113.43 (+0.43%)
AMC   2.79 (-6.38%)
PFE   25.39 (-0.12%)
PYPL   63.12 (-0.22%)
XOM   118.80 (+0.14%)
S&P 500   5,044.20 (+0.44%)
DOW   38,010.74 (+0.68%)
QQQ   426.29 (+0.11%)
AAPL   167.99 (+-0.01%)
MSFT   408.28 (-0.86%)
META   508.29 (+2.86%)
GOOGL   155.83 (+0.23%)
AMZN   181.19 (-0.05%)
TSLA   151.23 (-2.71%)
NVDA   848.87 (+1.01%)
AMD   154.98 (+0.62%)
NIO   3.99 (+2.05%)
BABA   69.28 (+0.67%)
T   16.14 (+0.12%)
F   12.11 (+0.58%)
MU   116.53 (+0.17%)
GE   157.67 (+1.28%)
CGC   6.91 (+6.47%)
DIS   113.43 (+0.43%)
AMC   2.79 (-6.38%)
PFE   25.39 (-0.12%)
PYPL   63.12 (-0.22%)
XOM   118.80 (+0.14%)
S&P 500   5,044.20 (+0.44%)
DOW   38,010.74 (+0.68%)
QQQ   426.29 (+0.11%)
AAPL   167.99 (+-0.01%)
MSFT   408.28 (-0.86%)
META   508.29 (+2.86%)
GOOGL   155.83 (+0.23%)
AMZN   181.19 (-0.05%)
TSLA   151.23 (-2.71%)
NVDA   848.87 (+1.01%)
AMD   154.98 (+0.62%)
NIO   3.99 (+2.05%)
BABA   69.28 (+0.67%)
T   16.14 (+0.12%)
F   12.11 (+0.58%)
MU   116.53 (+0.17%)
GE   157.67 (+1.28%)
CGC   6.91 (+6.47%)
DIS   113.43 (+0.43%)
AMC   2.79 (-6.38%)
PFE   25.39 (-0.12%)
PYPL   63.12 (-0.22%)
XOM   118.80 (+0.14%)
S&P 500   5,044.20 (+0.44%)
DOW   38,010.74 (+0.68%)
QQQ   426.29 (+0.11%)
AAPL   167.99 (+-0.01%)
MSFT   408.28 (-0.86%)
META   508.29 (+2.86%)
GOOGL   155.83 (+0.23%)
AMZN   181.19 (-0.05%)
TSLA   151.23 (-2.71%)
NVDA   848.87 (+1.01%)
AMD   154.98 (+0.62%)
NIO   3.99 (+2.05%)
BABA   69.28 (+0.67%)
T   16.14 (+0.12%)
F   12.11 (+0.58%)
MU   116.53 (+0.17%)
GE   157.67 (+1.28%)
CGC   6.91 (+6.47%)
DIS   113.43 (+0.43%)
AMC   2.79 (-6.38%)
PFE   25.39 (-0.12%)
PYPL   63.12 (-0.22%)
XOM   118.80 (+0.14%)
NASDAQ:MDXH

MDxHealth (MDXH) Stock Price, News & Analysis

$2.32
+0.02 (+0.87%)
(As of 10:16 AM ET)
Today's Range
$2.30
$2.35
50-Day Range
$2.30
$3.78
52-Week Range
$2.15
$4.64
Volume
1,174 shs
Average Volume
80,161 shs
Market Capitalization
$3.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.33

MDxHealth MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,131.9% Upside
$28.33 Price Target
Short Interest
Healthy
0.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.02) to ($0.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.15 out of 5 stars

MDXH stock logo

About MDxHealth Stock (NASDAQ:MDXH)

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

MDXH Stock Price History

MDXH Stock News Headlines

[Urgent!] Generational Wealth Gameplan
A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.
[Urgent!] Generational Wealth Gameplan
A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.
Mdxhealth Announces Resignation of Board Member
Mdxhealth Share Price (MDXH.BR)
mdxhealth: MDxHealth Reports Preliminary Q3-2023 Revenues
BTIG Sticks to Its Buy Rating for MDxHealth S.A. Sponsored ADR (MDXH)
MDxHealth Reports Q2 and Half Year 2023 Results
See More Headlines
Receive MDXH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MDxHealth and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
4/18/2024
Next Earnings (Estimated)
6/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Private households
Sub-Industry
N/A
Current Symbol
NASDAQ:MDXH
Employees
252
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.33
High Stock Price Target
$70.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+1,131.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$70.19 million
Book Value
$5.97 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Michael K. McGarrity (Age 61)
    CEO & Executive Director
    Comp: $579.32k
  • Mr. Ron Kalfus (Age 50)
    Chief Financial Officer
  • Mr. Joseph Sollee (Age 59)
    Executive VP of Corporate Development & General Counsel
  • Mr. John A. Bellano (Age 55)
    Chief Commercial Officer
  • Ms. Miriam Reyes (Age 51)
    Executive Vice President of Operations
  • Dr. Jason Poole Ph.D.
    Chief Scientific Officer

MDXH Stock Analysis - Frequently Asked Questions

Should I buy or sell MDxHealth stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MDxHealth in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDXH shares.
View MDXH analyst ratings
or view top-rated stocks.

What is MDxHealth's stock price target for 2024?

4 Wall Street research analysts have issued twelve-month price targets for MDxHealth's shares. Their MDXH share price targets range from $7.00 to $70.00. On average, they anticipate the company's stock price to reach $28.33 in the next year. This suggests a possible upside of 1,131.9% from the stock's current price.
View analysts price targets for MDXH
or view top-rated stocks among Wall Street analysts.

How have MDXH shares performed in 2024?

MDxHealth's stock was trading at $3.94 on January 1st, 2024. Since then, MDXH stock has decreased by 41.6% and is now trading at $2.30.
View the best growth stocks for 2024 here
.

Are investors shorting MDxHealth?

MDxHealth saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 17,100 shares, a decrease of 26.9% from the March 15th total of 23,400 shares. Based on an average daily volume of 84,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.1% of the shares of the company are sold short.
View MDxHealth's Short Interest
.

When is MDxHealth's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 5th 2024.
View our MDXH earnings forecast
.

How were MDxHealth's earnings last quarter?

MDxHealth SA (NASDAQ:MDXH) announced its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.39) earnings per share for the quarter. The firm earned $19.40 million during the quarter.

When did MDxHealth's stock split?

MDxHealth shares reverse split before market open on Friday, December 29th 2023. The 1-10 reverse split was announced on Monday, October 2nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What guidance has MDxHealth issued on next quarter's earnings?

MDxHealth updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $79.0 million-$81.0 million, compared to the consensus revenue estimate of $79.6 million.

When did MDxHealth IPO?

MDxHealth (MDXH) raised $45 million in an IPO on Thursday, November 4th 2021. The company issued 3,750,000 shares at $12.00 per share.

How do I buy shares of MDxHealth?

Shares of MDXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MDXH) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners